Millennium’s sNDA for Velecade for the treatment of relapsed mantle cell lymphoma (MCL) was granted Priority Review designation by the FDA. MCL is an aggressive, incurable subtype of non-Hodgkin’s lymphoma (NHL) for which there is no current standard of care. Priority Review is granted to compounds that address an unmet medical need and would be a significant improvement in treatment compared to existing therapies. The sNDA submission was based on Phase II data from the PINNAC...